Australia markets open in 1 hour 25 minutes

Sorrento Therapeutics, Inc. (SRNE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.7500+0.1200 (+4.56%)
At close: 04:00PM EDT
2.7000 -0.05 (-1.82%)
After hours: 06:34PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.04B
Enterprise value 1.02B
Trailing P/E N/A
Forward P/E 1.10
PEG ratio (5-yr expected) N/A
Price/sales (ttm)14.46
Price/book (mrq)4.58
Enterprise value/revenue 17.83
Enterprise value/EBITDA -2.12

Trading information

Stock price history

Beta (5Y monthly) 2.21
52-week change 3-69.20%
S&P500 52-week change 3-4.45%
52-week high 39.6300
52-week low 31.1500
50-day moving average 32.2890
200-day moving average 33.2871

Share statistics

Avg vol (3-month) 310.26M
Avg vol (10-day) 38.63M
Shares outstanding 5388.95M
Implied shares outstanding 6N/A
Float 8358.91M
% held by insiders 15.79%
% held by institutions 140.37%
Shares short (28 July 2022) 460.2M
Short ratio (28 July 2022) 46.21
Short % of float (28 July 2022) 415.66%
Short % of shares outstanding (28 July 2022) 415.48%
Shares short (prior month 29 June 2022) 460.07M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:25
Last split date 331 July 2013

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-679.18%

Management effectiveness

Return on assets (ttm)-32.96%
Return on equity (ttm)-206.57%

Income statement

Revenue (ttm)57.03M
Revenue per share (ttm)0.19
Quarterly revenue growth (yoy)29.00%
Gross profit (ttm)-167.05M
EBITDA -374.52M
Net income avi to common (ttm)-471.65M
Diluted EPS (ttm)-1.5270
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)270.66M
Total cash per share (mrq)0.71
Total debt (mrq)248.88M
Total debt/equity (mrq)110.03
Current ratio (mrq)1.62
Book value per share (mrq)0.62

Cash flow statement

Operating cash flow (ttm)-317.12M
Levered free cash flow (ttm)-160.27M